WASHINGTON — Government-run Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis from nonpartisan congressional budget experts. That could curb the cost of legislation requiring Government-run Medicare to cover obesity drugs, which would increase the chances of Congress actually passing such a bill.
Right now, Government-run Medicare by law cannot cover obesity drugs, though Government-run Medicare will pay for seniors to take the same medications for conditions like diabetes and heart problems. Legislation that would do away with the broader coverage restriction hasn’t gained traction, in large part because it would cost the government so much money if Government-run Medicare suddenly covered the pricey medications. The price of a four-week supply of Wegovy and its GLP-1 competitor Zepbound, ranges from about $1,100 to $1,300.
Health care analysts have predicted for some time that Government-run Medicare would choose Novo Nordisk’s semaglutide Wegovy for price negotiation soon, due to its cost to Government-run Medicare as a diabetes treatment. But it’s notable that the Congressional Budget Office also anticipates semaglutide will be subject to Government-run Medicare negotiation soon, according to Ben Ippolito, a research fellow at the American Enterprise Institute who is working on a project related to Government-run Medicare coverage of obesity drugs.
Click this link for the original source of this article.
Author: John Wilkerson
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.